Research Links Vitamin D, Omega-3, and Glucosamine to Faster Cognitive Decline in Older Adults

The focus of the research is on how these supplements behave differently in aging brains compared to younger ones. While doctors often modify medication dosages due to aging-related changes in metabolism and kidney function, similar guidelines for supplements are lacking. This gap is particularly relevant for households where older individuals take supplements alongside prescription medications, as the long-term effects on cognitive health are still unclear.

A January study in BMJ Open examined 5,065 participants aged 67.5 who were part of the Health and Retirement Study. Approximately 40% of these individuals used vitamin D supplements and, over six years, users exhibited slightly more rapid declines in cognition and executive function. The decline was noted only among users with normal blood levels of vitamin D, not those classified as deficient. Researchers suggested a potential link between excess vitamin D and molecular signaling related to the buildup of amyloid beta plaques, which are connected to Alzheimer's disease.

An April analysis in the Journal of Prevention of Alzheimer's Disease utilized imaging and cognitive data from the Alzheimer's Disease Neuroimaging Initiative, studying 273 omega-3 users against 546 nonusers over a median five years. Users showed faster cognitive decline across multiple clinical measures and lower glucose metabolism in brain areas susceptible to Alzheimer's, challenging previous assumptions about omega-3's benefits.

In June, a study published in Nature Metabolism investigated glucosamine through mouse models, postmortem human tissue, and electronic health records. Findings indicated a 25% higher likelihood of progressing to Alzheimer's or related dementia among glucosamine users and a similar increase in mortality rates in patients who already had dementia.

However, all three studies are observational, indicating patterns rather than direct causation. User characteristics—including income, education, and health behaviors—vary widely, complicating interpretations. For example, some individuals may initiate supplements due to existing cognitive symptoms, potentially skewing results. Additionally, variations in dosages and formulations of supplements can influence outcomes, as can incomplete records of usage.

Ramon Sun, the lead author of the glucosamine study, expressed surprise at the results but did not recommend discontinuing any supplements solely based on the findings. Onder Albayram from the Medical University of South Carolina found evidence indicating that a component of fish oil might impair recovery following brain injury, suggesting that age can significantly influence individual responses to supplements.

The uncertainty surrounding these findings is particularly prominent among adults aged 55 and older, including those with mild cognitive impairment and those who supplement despite normal vitamin D levels. For caregivers, the recommendation is to review all supplements at the next medical appointment, considering potential interactions with other medications and confirming the necessity of each product.

Larger, more conclusive studies are required to understand these associations better. Until then, researchers advise caution, emphasizing that these supplements are active compounds that may not be as harmless as previously thought.